Company attributes
Other attributes
About
Cortexyme is a San Francisco-based biotechnology company focusing on developing therapies and treatments for degenerative diseases, such as Alzheimer's. The company is expanding its therapeutics to target an undisclosed pathogen that's tied to neurodegeneration.
The company's lead therapeutic candidate is atuzaginstat (COR388). As of September 2020, the therapeutic is in Phase 2/3 of clinical trials with patients with mild to moderate Alzheimer's disease. The company's goal with this therapy is to target a pathogen in the brain that has shown to cause neurodegenerative conditions in animal models.
Cortexyme is conducting its GAIN trial with COR388, which is a novel virulence factor inhibitor targeting gingipains from P. gingivalis that have been found in the brain of Alzheimer's patients. The therapeutic is starting to show to block neuroinflammation and neurodegeneration in mice. The trial has over 500 participants and commenced in 2019. Results from the trial are expected to be complete by the end of 2021.
